Cargando…
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms
PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy(1–4), making PI3K an attractive target for cancer therapy. Despite the great promise of targeted therapy, resistance often develops, resulting in treatment failure. To elucidate mechanisms of resistance to PI3K-target...
Autores principales: | Liu, Pixu, Cheng, Hailing, Santiago, Stephanie, Raeder, Maria, Zhang, Fan, Isabella, Adam, Yang, Janet, Semaan, Derek J., Chen, Changzhong, Fox, Edward A., Gray, Nathanael S., Monahan, John, Schlegel, Robert, Beroukhim, Rameen, Mills, Gordon B., Zhao, Jean J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169724/ https://www.ncbi.nlm.nih.gov/pubmed/21822287 http://dx.doi.org/10.1038/nm.2402 |
Ejemplares similares
-
PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015) -
Treatment of Frequently Recurring “Erysipelas” of the Face
Publicado: (1881) -
Treatment of Frequently Recurring “Erysipelas” of the Face
Publicado: (1882) -
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016) -
Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)